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Engraftment Syndrome Has Distinct Biology Compared
with Graft Versus Host Disease
Pooja Khandelwal, Sabine Mellor-Heinke, Stella Davies,
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Najibah Rehman, Kristi Smiley, Joyce Villanueva,
Alexandra Filipovich. Bone Marrow Transplantation and
Immune Deﬁciency, Cincinnati Children's Hospital Medical
Center, Cincinnati, OH
Introduction: The biology of engraftment syndrome (ES) is
poorly understood and the degree of overlap with GVHD is
unclear.
Methods: To better understand ES, plasma cytokine proﬁles
were evaluated in 52 consecutive pediatric allogeneic bone
marrow transplant recipients prior to transplant, on the day
of stem cell infusion and weekly until day+100. Patients were
divided into three groups, those with isolated engraftment
syndrome (n¼4), acute graft versus host disease without
prior ES (n¼12) and with neither engraftment syndrome nor
acute graft versus host disease (n¼32). Cytokine values were
expressed as mean fold increase from pre transplant values.
Results: Median age of recipients was 6.7 years (range 0.6-
19.4). ES was observed a median of 12.5 days (range 11-15)
after transplant, while aGVHD was diagnosed at median of
55 days (range 19-95 days) after transplant. MCP-1 and
MIP1b were signiﬁcantly elevated in patients with ES during
the ﬁrst two weeks, while remaining unchanged or reduced
in either of the other 2 cohorts. Moreover, while various
cytokines were found to be elevated in patients who devel-
oped aGVHD, the degree of elevation was signiﬁcantly
exaggerated in patients with isolated ES during 4 weeks
post-transplant. (See table 1)
Conclusion: MCP-1 and MIP1b are elevated speciﬁcally in ES
suggesting a separate biology from GVHD. In addition, the
degreeofelevationofpro-inﬂammatorycytokines ismarkedly
greater in children with ES compared to those with GVHD.
Figure 1. MIP1bandMCP1 inpatientswithES, aGVHDandneitherGVHDnorES.Table 1
Cytokine proﬁles in ES, aGVHD and patients with neither ES nor GVHD at 4
weeks after transplant
Cytokine Neither ES nor
GVHD (Mean
fold increase
from pre
transplant
value)
GVHD (Mean
fold increase
from pre
transplant
values)
ES (Mean fold
increase from
pre transplant
values)
P-value
(ES vs
GVHD)
IL1b 0 2 36 <.01
IL4 2 5 40 <.001
IL7 8 6 138 <.01
IL12 14 4.6 108 <.01
IL13 2.8 3 62 <.0195
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Matched related hemopoietic stem cell transplantation
(MRD-HSCT) for patients with Primary Immunodeﬁciencies
(PIDs) has been life saving. There is less information regarding
stem cell transplantation from unrelated donors including
umbilical cord blood units. We report the outcome following
HSCT (1998-2012) in 69 patients with PIDs: SCID (n¼35),WAS
(n¼9), Phagocytic disorders (CGD (n¼17), LAD (n¼4)); and
other (n¼4; one each; Interferon g receptor deﬁciency, Hyper
IgM syndrome, Autosomal recessive Hyper IgE syndrome
(Dock 8 mutation), and reticular dysgenesis). The median age
at transplant was 1 year (range, 0.1-17 years). Twenty patients
received an MRD graft, 22 patients received a matched unre-
lated donor graft (MUD), 4 patients received a mismatched
unrelated donor graft, 15 patients received a haploidentical
related donor graft and 9 patients received a mismatched
unrelated cord blood unit (MMUCB). One patient received
a MMUCB after a haploidentical graft failure. 58 patients
received ablative conditioning regimen with busulfan, cyclo-
phosphamide, and ﬂudarabine or cytarabine. Six patients
received reduced intensity conditioning using ﬂudarabine
with anti-CD52 or/and anti-CD45. Six SCID patients were not
conditioned. 52 patients received anti-CD52; no serotherapy
was given forMMUCB grafts. Graft versus host disease (GvHD)
prophylaxis combined cyclosporine and methotrexate or
cyclosporine and prednisone except for MUCB recipients who
were given cyclosporine and MMF as prophylaxis. Engraft-
ment: Forty ﬁve of 67 evaluable patients (65%) achieved full
donor chimerism (>90%) of all cell lineages including T cells.
Twelve patients had primary graft failure. 10 were hap-
loidentical grafts and 2 were MUD grafts. All except one were
rescued with a repeat stem cell infusion. Just 3/67 patients
developedgrade II-IVaGvHDandnopatientdevelopedchronic
GvHD. Survival.With amedian followupof 4 years (range, 0.3-
12 years), overall survival was: 95% and 86%, for phagocytic
disordersandSCIDs respectively; and77%and75% forWASand
other diseases, respectively. Recipients of MRD and UCB had
100% survival:MUDgraft recipients had an 88% survival, while
recipients of mismatched unrelated or haploidentical related
transplants, had 50% and 71% survival respectively. Infection
was the commonest cause of death. Hence excellent overall
survival for PID patientsmay be obtained after unrelated HSCT
and results usingmatched related grafts andmismatched cord
blood units are highly comparable.96
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